Literature DB >> 10938026

Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.

B Wiman1, T Andersson, J Hallqvist, C Reuterwall, A Ahlbom, U deFaire.   

Abstract

An impaired fibrinolytic function due to elevated plasma levels of plasminogen activator inhibitor (PAI)-1 activity or tissue plasminogen activator (tPA) antigen is correlated with the development of myocardial infarction (MI) in patients with manifest coronary heart disease. Recently, methods for determining the specific tPA/inhibitor complexes constituting tPA antigen in plasma have become available. In the Stockholm Heart Epidemiology Program (SHEEP) study, 86 of 1212 MI patients, subjected to blood sampling in a metabolically stable period, suffered reinfarction before the end of 1996. These individuals have been compared with an approximately equal number of matched MI patients without recurrence and a group of matched healthy control subjects regarding the plasma concentrations of some hemostatic factors. The hemostatic compounds studied (fibrinogen, von Willebrand factor, tPA antigen, PAI-1, and the tPA/PAI-1 complex) were typically higher in the groups (men and women) with recurrence of MI compared with those without. The plasma concentrations were also typically higher in the pooled groups of patients compared with the groups of healthy control subjects. The largest between-group differences were found for the plasma tPA/PAI-1 complex. The crude odds ratio for reinfarction associated with higher concentration (>/=75th percentile among the control subjects) of tPA/PAI-1 was 1.8 (95% CI 1.1 to 3.1); the corresponding crude odds ratio for von Willebrand factor was 2.3 (1. 3 to 4.0). The tPA/PAI-1 complex correlated strongly with PAI-1 and tPA antigen in all groups and with serum triglycerides and body mass index in all groups except for women with reinfarction. An increased plasma level of tPA/PAI-1 complex is a novel risk marker for recurrent MI in men and women. Most likely, increased plasma levels of tPA/PAI-1 complex reflect impaired fibrinolysis, because the correlation with PAI-1 is strong. Further support is obtained indicating that the plasma concentration of von Willebrand factor is also an important risk marker for recurrent MI.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10938026     DOI: 10.1161/01.atv.20.8.2019

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  41 in total

1.  Prothrombotic markers in asymptomatic dyslipidemic subjects.

Authors:  David Karasek; Helena Vaverkova; Milan Halenka; Dagmar Jackuliakova; Zdenek Frysak; Ludek Slavik; Dalibor Novotny
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

2.  Uridine triphosphate (UTP) induces profibrotic responses in cardiac fibroblasts by activation of P2Y2 receptors.

Authors:  Oscar O Braun; David Lu; Nakon Aroonsakool; Paul A Insel
Journal:  J Mol Cell Cardiol       Date:  2010-05-13       Impact factor: 5.000

3.  Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1.

Authors:  Jacqueline M Cale; Shih-Hon Li; Mark Warnock; Enming J Su; Paul R North; Karen L Sanders; Maria M Puscau; Cory D Emal; Daniel A Lawrence
Journal:  J Biol Chem       Date:  2010-01-08       Impact factor: 5.157

4.  Proteomic biomarkers of sleep apnea.

Authors:  Aditya Ambati; Yo-El Ju; Ling Lin; Alexander N Olesen; Henriette Koch; Julien Jacques Hedou; Eileen B Leary; Vicente Peris Sempere; Emmanuel Mignot; Shahrad Taheri
Journal:  Sleep       Date:  2020-11-12       Impact factor: 5.849

5.  In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban.

Authors:  Shu He; Håkan Wallèn; Niklas Bark; Margareta Blombäck
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

Review 6.  von Willebrand factor: at the crossroads of bleeding and thrombosis.

Authors:  Cécile V Denis; Peter J Lenting
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

7.  Palmitate and insulin synergistically induce IL-6 expression in human monocytes.

Authors:  Robert C Bunn; Gael E Cockrell; Yang Ou; Kathryn M Thrailkill; Charles K Lumpkin; John L Fowlkes
Journal:  Cardiovasc Diabetol       Date:  2010-11-05       Impact factor: 9.951

8.  Cardiovascular risk associated with interactions among polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems.

Authors:  John P Bentley; Folkert W Asselbergs; Christopher S Coffey; Patricia R Hebert; Jason H Moore; Hans L Hillege; Wiek H van Gilst
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

9.  Thyroid Function Within the Reference Range and the Risk of Stroke: An Individual Participant Data Analysis.

Authors:  Layal Chaker; Christine Baumgartner; Wendy P J den Elzen; Tinh-Hai Collet; M Arfan Ikram; Manuel R Blum; Abbas Dehghan; Christiane Drechsler; Robert N Luben; Marileen L P Portegies; Giorgio Iervasi; Marco Medici; David J Stott; Robin P Dullaart; Ian Ford; Alexandra Bremner; Anne B Newman; Christoph Wanner; José A Sgarbi; Marcus Dörr; W T Longstreth; Bruce M Psaty; Luigi Ferrucci; Rui M B Maciel; Rudi G Westendorp; J Wouter Jukema; Graziano Ceresini; Misa Imaizumi; Albert Hofman; Stephan J L Bakker; Jayne A Franklyn; Kay-Tee Khaw; Douglas C Bauer; John P Walsh; Salman Razvi; Jacobijn Gussekloo; Henry Völzke; Oscar H Franco; Anne R Cappola; Nicolas Rodondi; Robin P Peeters
Journal:  J Clin Endocrinol Metab       Date:  2016-09-07       Impact factor: 5.958

10.  Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1.

Authors:  Frédéric Mouquet; François Cuilleret; Sophie Susen; Karine Sautière; Philippe Marboeuf; Pierre Vladimir Ennezat; Eugène McFadden; Pascal Pigny; Florence Richard; Bernadette Hennache; Marie Christine Vantyghem; Michel Bertrand; Jean Dallongeville; Brigitte Jude; Eric Van Belle
Journal:  Eur Heart J       Date:  2009-01-22       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.